MWPCG
TECH icon

Measured Wealth Private Client Group’s Bio-Techne TECH Stock Holding History

Measured Wealth Private Client Group’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.8K Sell
464
-115
-20% -$6.21K 0.01% 393
2026
Q1 		$30.3K Hold
579
– – 0.01% 376
2025
Q4 		$34.1K Hold
579
– – 0.01% 364
2025
Q3 		$32.2K Buy
+579
New +$31K 0.01% 375

Other funds holding TECH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Measured Wealth Private Client Group's TECH Position: Q2 2026 in Review

Measured Wealth Private Client Group reduced its Bio-Techne (TECH) stake by 20% in Q2 2026, selling an estimated $6.21K and leaving 464 shares worth $32.8K. The position accounts for 0.01% of the portfolio, ranked #393.

Measured Wealth Private Client Group first reported a position in TECH in Q3 2025 and has held it in 4 quarters since. The position peaked at $34.1K in Q4 2025. 593 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

  • Measured Wealth Private Client Group held 464 shares of Bio-Techne worth $32.8K as of Q2 2026.
  • Measured Wealth Private Client Group sold 115 Bio-Techne shares in Q2 2026, an estimated $6.21K.
  • Bio-Techne made up 0.01% of Measured Wealth Private Client Group's portfolio in Q2 2026, its #393 holding.
  • Measured Wealth Private Client Group first reported a position in Bio-Techne in Q3 2025 and has held it in 4 quarters since.
  • Measured Wealth Private Client Group's Bio-Techne position peaked at $34.1K in Q4 2025.
  • 593 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2026, filed 10 Aug 2026.